Up to 4000 patients could be offered voxelotor (Oxbryta), a treatment for sickle cell disease which may reduce the need for blood transfusions, after the drug was recommended by the UK National Institute for Health and Care Excellence (NICE) in final draft guidance.1
Voxelotor, a once daily pill, will now be available on the NHS in England for people aged 12 and older and for whom hydroxycarbamide alone is insufficient or where the patient cannot take hydroxycarbamide. NICE has said clinical …